Literature DB >> 11298451

Leptin-regulated endocannabinoids are involved in maintaining food intake.

V Di Marzo1, S K Goparaju, L Wang, J Liu, S Bátkai, Z Járai, F Fezza, G I Miura, R D Palmiter, T Sugiura, G Kunos.   

Abstract

Leptin is the primary signal through which the hypothalamus senses nutritional state and modulates food intake and energy balance. Leptin reduces food intake by upregulating anorexigenic (appetite-reducing) neuropeptides, such as alpha-melanocyte-stimulating hormone, and downregulating orexigenic (appetite-stimulating) factors, primarily neuropeptide Y. Genetic defects in anorexigenic signalling, such as mutations in the melanocortin-4 (ref. 5) or leptin receptors, cause obesity. However, alternative orexigenic pathways maintain food intake in mice deficient in neuropeptide Y. CB1 cannabinoid receptors and the endocannabinoids anandamide and 2-arachidonoyl glycerol are present in the hypothalamus, and marijuana and anandamide stimulate food intake. Here we show that following temporary food restriction, CB1 receptor knockout mice eat less than their wild-type littermates, and the CB1 antagonist SR141716A reduces food intake in wild-type but not knockout mice. Furthermore, defective leptin signalling is associated with elevated hypothalamic, but not cerebellar, levels of endocannabinoids in obese db/db and ob/ob mice and Zucker rats. Acute leptin treatment of normal rats and ob/ob mice reduces anandamide and 2-arachidonoyl glycerol in the hypothalamus. These findings indicate that endocannabinoids in the hypothalamus may tonically activate CB1 receptors to maintain food intake and form part of the neural circuitry regulated by leptin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11298451     DOI: 10.1038/35071088

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  404 in total

Review 1.  Novel physiologic functions of endocannabinoids as revealed through the use of mutant mice.

Authors:  G Kunos; S Bátkai
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

2.  The cannabinoid receptor antagonist SR 141716 attenuates overfeeding induced by systemic or intracranial morphine.

Authors:  Aaron N A Verty; Malini E Singh; Iain S McGregor; Paul E Mallet
Journal:  Psychopharmacology (Berl)       Date:  2003-04-17       Impact factor: 4.530

3.  The emerging science of body weight regulation and its impact on obesity treatment.

Authors:  Judith Korner; Louis J Aronne
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

4.  The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.

Authors:  Eleni T Tzavara; Richard J Davis; Kenneth W Perry; Xia Li; Craig Salhoff; Frank P Bymaster; Jeffrey M Witkin; George G Nomikos
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

5.  Circadian rhythm of circulating levels of the endocannabinoid 2-arachidonoylglycerol.

Authors:  E C Hanlon; E Tasali; R Leproult; K L Stuhr; E Doncheck; H de Wit; C J Hillard; E Van Cauter
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

Review 6.  The endocannabinoid system: role in energy regulation.

Authors:  Thomas F Gamage; Aron H Lichtman
Journal:  Pediatr Blood Cancer       Date:  2012-01       Impact factor: 3.167

7.  2-arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism.

Authors:  Kwang-Mook Jung; Jason R Clapper; Jin Fu; Giuseppe D'Agostino; Ana Guijarro; Dean Thongkham; Agnesa Avanesian; Giuseppe Astarita; Nicholas V DiPatrizio; Andrea Frontini; Saverio Cinti; Sabrina Diano; Daniele Piomelli
Journal:  Cell Metab       Date:  2012-03-07       Impact factor: 27.287

Review 8.  Antagonizing the cannabinoid receptor type 1: a dual way to fight obesity.

Authors:  D Cota; S Genghini; R Pasquali; U Pagotto
Journal:  J Endocrinol Invest       Date:  2003-10       Impact factor: 4.256

9.  Structural equation modeling of food craving across the menstrual cycle using behavioral, neuroendocrine, and metabolic factors.

Authors:  Sridevi Krishnan; Karan Agrawal; Rebecca R Tryon; Lucas C Welch; William F Horn; John W Newman; Nancy L Keim
Journal:  Physiol Behav       Date:  2018-07-18

Review 10.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.